Wall Street brokerages expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will report $158.42 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for AMAG Pharmaceuticals’ earnings. The lowest sales estimate is $155.65 million and the highest is $160.89 million. AMAG Pharmaceuticals posted sales of $127.42 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 24.3%. The business is expected to announce its next earnings report before the market opens on Thursday, August 3rd.

On average, analysts expect that AMAG Pharmaceuticals will report full year sales of $158.42 million for the current year, with estimates ranging from $640.13 million to $655.96 million. For the next financial year, analysts expect that the business will report sales of $552.67 million per share, with estimates ranging from $481.01 million to $620.89 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by $1.15. The business had revenue of $139.47 million for the quarter, compared to analyst estimates of $150.32 million. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The business’s revenue for the quarter was up 27.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.22) earnings per share.

A number of brokerages have recently weighed in on AMAG. ValuEngine lowered shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Citigroup Inc. reduced their price objective on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Barclays PLC restated a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a report on Monday, May 15th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $34.00 price objective (down from $40.00) on shares of AMAG Pharmaceuticals in a report on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $28.09.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 1.05% during trading on Friday, hitting $19.30. The stock had a trading volume of 127,893 shares. AMAG Pharmaceuticals has a one year low of $16.00 and a one year high of $36.83. The stock’s market cap is $676.37 million. The stock’s 50 day moving average price is $18.21 and its 200-day moving average price is $21.64.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.80% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Comerica Bank increased its position in shares of AMAG Pharmaceuticals by 5.1% in the fourth quarter. Comerica Bank now owns 36,399 shares of the specialty pharmaceutical company’s stock valued at $837,000 after buying an additional 1,764 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of AMAG Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 406,303 shares of the specialty pharmaceutical company’s stock valued at $14,140,000 after buying an additional 6,507 shares during the last quarter. New York State Teachers Retirement System increased its position in shares of AMAG Pharmaceuticals by 5.0% in the fourth quarter. New York State Teachers Retirement System now owns 25,325 shares of the specialty pharmaceutical company’s stock valued at $881,000 after buying an additional 1,200 shares during the last quarter. Thrivent Financial for Lutherans increased its position in shares of AMAG Pharmaceuticals by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 18,380 shares of the specialty pharmaceutical company’s stock valued at $640,000 after buying an additional 1,000 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at about $19,914,000.

TRADEMARK VIOLATION NOTICE: This story was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/21/amag-pharmaceuticals-inc-amag-expected-to-post-quarterly-sales-of-158-42-million.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.